Spinal Muscular Atrophy - Onasemnogene Abeparvovec-Xioi (Zolgensma®)

WA.PHAR.74 Spinal Muscular Atrophy (Zolgensma®)

Effective Date: July 1, 2019

Background:

Gene therapy for spinal muscular atrophy using onasemnogene abeparvovec-xioi, marketed as Zolgensma®, is managed and paid by the Health Care Authority for Medicaid members.

All requests for authorization or payment must be referred to the Health Care Authority.

Coding:

HCPCS Code	Description
C9399	Unclassified drugs or biologicals
J3490	Unclassified drugs
J3590	Unclassified biologics

National Drug Codes			
71894-120-02	71894-126-04	71894-132-06	71894-137-08
71894-121-03	71894-127-05	71894-133-07	71894-138-08
71894-122-03	71894-128-05	71894-134-07	71894-139-09
71894-123-03	71894-129-05	71894-135-07	71894-140-09
71894-124-04	71894-130-06	71894-136-08	71894-141-09
71894-125-04	71894-131-06		